首页> 美国卫生研究院文献>Avicenna Journal of Medical Biotechnology >Construction and Production of Foxp3-Fc (IgG) DNA Vaccine/Fusion Protein
【2h】

Construction and Production of Foxp3-Fc (IgG) DNA Vaccine/Fusion Protein

机译:Foxp3-Fc(IgG)DNA疫苗/融合蛋白的构建和生产

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background:It seems that the success of vaccination for cancer immunotherapy such as Dendritic Cell (DC) based cancer vaccine is hindered through a powerful network of immune system suppressive elements in which regulatory T cell is the common factor. Foxp3 transcription factor is the most specific marker of regulatory T cells. In different studies, targeting an immune response against regulatory cells expressing Foxp3 and their removal have been assessed. As these previous studies could not efficiently conquer the suppressive effect of regulatory cells by their partial elimination, an attempt was made to search for constructing more effective vaccines against regulatory T cells by which to improve the effect of combined means of immunotherapy in cancer. In this study, a DNA vaccine and its respective protein were constructed in which Foxp3 fused to Fc(IgG) can be efficiently captured and processed by DC via receptor mediated endocytosis and presented to MHCII and I (cross priming).
机译:背景:看来,通过强大的免疫系统抑制元件网络(其中调节性T细胞是常见因素)阻碍了针对癌症免疫疗法(例如基于树突细胞(DC)的癌症疫苗)的疫苗接种的成功。 Foxp3转录因子是调节性T细胞的最特异性标记。在不同的研究中,已经针对靶向针对表达Foxp3的调节细胞的免疫应答及其去除进行了评估。由于这些先前的研究不能通过部分消除而有效地克服调节细胞的抑制作用,因此尝试寻找构建针对调节性T细胞的更有效的疫苗,以提高组合免疫疗法在癌症中的作用。在这项研究中,构建了DNA疫苗及其各自的蛋白质,其中与Fc(IgG)融合的Foxp3可以通过受体介导的内吞作用被DC有效捕获和加工,并呈递给MHCII和I(交叉引物)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号